The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
December 2nd 2024
Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.
November 27th 2024
November 26th 2024
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Defining Osteoarthritis: What It Is, and What It Is Not
September 9th 2010Synovial inflammation in osteoarthritis (OA) is secondary to mechanical damage to the articular cartilage and bone. OA often is said to be a disease of weight-bearing joints, but it is more appropriate to consider them as load-bearing joints. OA is the failure of an organ, the synovial joint.
Managing Foot and Ankle Injuries in Athletes
September 9th 2010Physicians who treat athletes with traumatic foot and ankle injuries should know when to order special imaging studies, determine whether injuries can be managed in the office or require referral, and return the athlete to sports activity quickly. For simple ankle sprains, plain x-ray films usually are not indicated; functional rehabilitation is a first-line treatment.
Hepatitis C–Related Arthropathy: Diagnostic and Treatment Considerations
September 9th 2010Hepatitis C–related arthropathy is one of the most common extrahepatic manifestations of hepatitis C virus (HCV) infection. Although symptoms can be disabling, the prognosis typically is benign. Patients who have atypical chronic inflammatory arthritis with an unknown cause should be evaluated for HCV infection.
Revised RA classification criteria allow for earlier study of treatments
September 8th 2010Newly revised classification criteria for rheumatoid arthritis (RA) will allow for the study of treatments at much earlier disease stages and lead to better patient outcomes, according to the American College of Rheumatology (ACR), which created the new criteria in collaboration with the European League Against Rheumatism (EULAR).
New treatment for severe vasculitis?
September 7th 2010A new strategy for treating patients who have antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a severe form of vasculitis, provides the same benefits as the current standard of care used for more than 40 years but requires less frequent treatments.
ACL update: Lubrication key to preventing osteoarthritis after injury
September 6th 2010The researchers used animal models with torn ACLs to test 3 types of fluids that could be injected into the joints to serve as a substitute for lost synovial fluid: human synoviocyte lubricin that was created in a culture and then purified to be
Reaching RA remission is a realistic goal
September 3rd 2010Remission is a realistic goal for patients with rheumatoid arthritis (RA), especially with intensive combination treatment regimens provided early in the disease course. The Disease Activity Score 28 (DAS28) remission criteria appear to be easiest to achieve.
Lupus in Men: All in the Genes?
September 3rd 2010There may be genetic susceptibility factors for systemic lupus erythematosus (SLE) that act only in men. In about 1% of families with SLE, all the patients with SLE are male and the women universally have positive antinuclear antibodies; also, men with SLE have more children with SLE than do women with SLE.
Cardiometabolic risk in youths: Fatness outweighs fitnes
September 3rd 2010Both fatness and fitness are associated with cardiometabolic risk factors in American youths, but fatness associations are stronger. Although maintaining high levels of fitness and preventing obesity may affect cardiometabolic risk factors positively, obesity prevention may have greater benefit.
Ultrasonographic guidance boosts joint injection accuracy
September 3rd 2010Corticosteroid injection in the joints of patients with inflammatory arthritis results in significant alleviation of symptoms and improvement in functional status. Ultrasonography (US)-guided injections are significantly more accurate than clinical examination (CE)-guided injections.